The concept of targeted protein degradation
presents revolutionary drug development opportunities and is anticipated to
bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis
targeting chimera (PROTAC), was developed about a decade ago. Presently, a
variety of other such chemical entities and molecular glues are under
investigation. In fact, certain pipeline candidates are already in the mid to
late-phase trials and are anticipated to soon enter the market.
To order this 330+ page report, which features 130+ figures
and 145+ tables, please visit this link
The USD 3.6 billion (by 2030) financial opportunity
within the target protein degradation market has been analyzed across the
following segments:
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
The Targeted Protein Degradation Market: Focus on Therapeutics
and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome
Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs,
Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB
Inhibitors), 2020-2030 report features the
following companies, which we identified to be key players in this domain:
§
§
§
§
§
§
§
§
§
§
Table of Contents
1. Preface
4. Current Market Landscape
5. Company Profiles
6. Clinical Trial Analysis
7. KOL Analysis
8. Publication Analysis
9. Funding and Investment
Analysis
10. Partnerships and
Collaborations
11. Market Sizing and Opportunity Analysis
12. Executive Insights
13. Concluding Remarks
14. Appendix 1: Tabulated Data
15. Appendix 2: List of
Companies and Organizations
To purchase a copy, please visit
https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415